Chicago, RSNA 2013 -- Gamma Medica, Inc. debuts a range of enhancements to its LumaGEM molecular breast imaging (MBI) system at the Radiological Society of North America (RSNA) 2013 conference, as the company expands sales and marketing efforts for its groundbreaking breast imaging technology. 

New for LumaGEM at RSNA 2013 is a redesigned collimator increasing sensitivy by 20%.  This new design will accelerate image acquisition and decrease the procedural time.  Additionally, the company introduces an improved breast compression system designed to maximize patient stability, helping to ensure consistent, high-quality images. 

The latest evolution in a new generation of functional breast imaging, MBI technology is a high-resolution imaging system that provides a more diagnostically specific, less costly and easier-to-interpret alternative to breast MRI in many similar applications. 

LumaGEM detects tumors as small as five millimeters in mammographically dense and other difficult-to-image breast tissue.  The technology is distinguished from mammography by its ability to visualize tumors surrounded by non-cancerous glandular tissue, which often goes undetected  on mammograms.  Studies also show MBI also may be superior to mammography  for imaging women with difficult-to-detect lobular tumors, scar tissue from previous surgeries, implants and small distant metastases.

“More than 40 percent of women have dense breast tissue,” says Gamma Medica president and CEO Jim Calandra.  “Both physicians and patients themselves have become increasingly aware of the shortcomings of mammography in imaging these women. The result has been growing advocacy and legislation supporting the needs of women with dense breasts.  MBI is an advanced technology that can make an important difference for this population.  Gamma Medica has the resources and commitment to deliver on that promise.”

These and other enhancements follow a $16 million Series A round of financing last summer from healthcare investment firm Psilos Group Managers and the opening of a new world headquarters in Salem, NH in August.  

About Gamma Medica, Inc.

Gamma Medica, Inc. is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company designs, builds and services the LumaGEM^® MBI system, the first commercially available, FDA-cleared planar, dual head, fully
solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular
breast imaging.  For more information, visit www.gammamedica.com